Literature DB >> 7025304

Hemobilia.

J E Goodnight, F W Blaisdell.   

Abstract

Hemobilia is a relatively rare manifestation of hepatobiliary disease that is usually characterized by recurrent colicky upper abdominal pain, gastrointestinal bleeding, and obstructive jaundice. In most instances, hemobilia presents as complication of liver injury, blunt abdominal trauma, or liver surgery. Other causes are percutaneous diagnostic procedures, hepatic artery aneurysms, inflammatory disease, biliary tract stones, and liver and bile duct neoplasms. The diagnosis of hemobilia is confirmed by endoscopy and selective angiography. Treatment of hemobilia is primarily surgical, with direct exploration of the liver, ligation of the bleeding point, and relief of bile duct obstruction. If liver damage is minimal, nonoperative management may be successful but requires careful observation and serial arteriography.

Entities:  

Mesh:

Year:  1981        PMID: 7025304     DOI: 10.1016/s0039-6109(16)42493-x

Source DB:  PubMed          Journal:  Surg Clin North Am        ISSN: 0039-6109            Impact factor:   2.741


  5 in total

1.  Early carcinoma of the gallbladder accompanied by hemobilia: report of a case.

Authors:  K Uchiyama; N Aida; T Shibuya; S Tanaka
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

Review 2.  Potentially fatal haemobilia due to inappropriate use of an expanding biliary stent.

Authors:  Rakesh Rai; John Rose; Derek Manas
Journal:  World J Gastroenterol       Date:  2003-10       Impact factor: 5.742

3.  Hemobilia--successful treatment by angiographic embolization.

Authors:  M Lee; H S Himal
Journal:  Surg Endosc       Date:  1992 Mar-Apr       Impact factor: 4.584

4.  Management of massive haemobilia in an Indian hospital.

Authors:  Mudit Kumar; Subhash Gupta; Arvinder Soin; Samiran Nundy
Journal:  Indian J Surg       Date:  2008-12-23       Impact factor: 0.656

5.  Hemobilia from ruptured hepatic artery aneurysm in polyarteritis nodosa.

Authors:  Sung Soon Park; Byeong Uk Kim; Hye Suk Han; Ja Chung Goo; Joung Ho Han; Il Hun Bae; Seon Mee Park
Journal:  Korean J Intern Med       Date:  2006-03       Impact factor: 2.884

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.